<DOC>
	<DOCNO>NCT01606384</DOCNO>
	<brief_summary>Primary Objective : - To evaluate effect two fixed dos SSR149415 ( 250 mg bid 100 mg bid ) hypothalamic-pituitary-adrenal axis function patient major depressive disorder . Secondary Objectives : - To evaluate tolerability safety SSR149415 patient major depressive disorder . - To evaluate efficacy two fixed dos SSR149415 compare placebo patient major depressive disorder . - To evaluate plasma concentration SSR149415 .</brief_summary>
	<brief_title>Evaluation Potential Effects SSR149415 Hypothalamic-pituitary-adrenal Axis Outpatients With Major Depressive Disorder</brief_title>
	<detailed_description>The study consist three segment ( A , B C ) . Segment A 1 4-week , drug-free , screening baseline period . Segment B 4-week , double-blind period . After last dose double-blind study medication Segment B , patient enter Segment C , 1-week drug-free , follow-up period . The total study duration one patient participate segment study 6 week .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Vasopressins</mesh_term>
	<mesh_term>Arginine Vasopressin</mesh_term>
	<criteria>Inclusion criterion : Diagnosis major depressive disorder define Diagnostic Statistical Manual Mental Disorders , 4th EditionText Revision ( DSMIVTR ) Mini International Neuropsychiatric Interview ( MINI ) criterion . Exclusion criterion : Outpatients unwilling hospitalize total 6 night 8 day . Total score le 21 ( &lt; 21 ) 17item Hamilton Depression Rating Scale ( HAMD ) Visit 1 ( Day 7 ) Visit 5 ( Day 1 ) . Patients whose current depressive episode diagnose psychotic feature , catatonic feature , seasonal pattern postpartum onset secondary general medical disorder . Patients alcohol dependence abuse substance dependence abuse past 12 month accord MINI , except nicotine caffeine dependence . Patients use follow prior entry Segment B : antipsychotic within 3 month ; fluoxetine within 1 month ; monoamine oxidase inhibitor ( MAOI ) within 2 week ; antidepressant , anxiolytic , sedativehypnotic , moodstabilizer ( lithium , anticonvulsant ) within 7 day except permitted concomitant medication The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>